<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2924">
  <stage>Registered</stage>
  <submitdate>20/09/2010</submitdate>
  <approvaldate>20/09/2010</approvaldate>
  <nctid>NCT01207440</nctid>
  <trial_identification>
    <studytitle>Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)</studytitle>
    <scientifictitle>A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia</scientifictitle>
    <utrn />
    <trialacronym>PACE</trialacronym>
    <secondaryid>2010-020414-28</secondaryid>
    <secondaryid>AP24534-10-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Myeloid Leukemia</healthcondition>
    <healthcondition>Ph+ Acute Lymphoblastic Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ponatinib

Experimental: CP-CML R/I - Chronic Phase (CP) CML resistant or intolerant (R/I) to dasatinib or nilotinib

Experimental: AP-CML R/I - Accelerated Phase (AP) CML resistant or intolerant (R/I) to dasatinib or nilotinib

Experimental: Blast Phase (BP) CML / Ph+ ALL - Blast Phase (BP) CML or Ph+ ALL resistant or intolerant (R/I) to dasatinib or nilotinib or Ph+ ALL resistant or intolerant (R/I) to dasatinib or nilotinib

Experimental: CP-CML with T315I mutation - CP-CML patients who have the T315I mutation of BCR-ABL

Experimental: AP-CML with T315I mutation - AP-CML patients who have the T315I mutation of BCR-ABL

Experimental: BP-CML / Ph+ ALL with T315I mutation - BP-CML or Ph+ ALL patients who have the T315I mutation of BCR-ABL


Treatment: drugs: Ponatinib
45 mg dose taken orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Major cytogenetic response (MCyR) in CP-CML patients - Defined as complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR).</outcome>
      <timepoint>up to 48 months after first dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Major hematologic response (MaHR) in AP-CML patients - Consists of complete hematologic response (CHR) or no evidence of leukemia (NEL)</outcome>
      <timepoint>up to 48 months after first dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>MaHR in BP-CML/Ph+ALL patients - Consists of CHR or NEL</outcome>
      <timepoint>up to 48 months after first dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Responses in CP-CML patients - The composite of:
Hematologic responses: CHR;
Cytogenetic responses: confirmed MCyR; and
Molecular response: major molecular response (MMR).</outcome>
      <timepoint>up to 48 months after first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Responses in AP-CML or BP-CML/Ph+ ALL patients - The composite of:
Cytogenetic responses: CCyR, PCyR, confirmed MCyR; and
Molecular response: MMR.</outcome>
      <timepoint>up to 48 months after first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Responses in all patients - The composite of time to response, duration of response, progression free survival, and overall survival.</outcome>
      <timepoint>up to 48 months after first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability for all patients - The Adverse Event (AE) incidence rates as well as the frequency of occurrence of overall toxicity, categorized by toxicity grades (severity) will be described for each cohort of the trial. Listings of laboratory test results will also be generated, and descriptive statistics summarizing the changes in laboratory tests over time will be presented.</outcome>
      <timepoint>up to 48 months after first dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL

          -  Previously treated with and developed resistance or intolerance to dasatinib or
             nilotinib OR developed the T3151 mutation after any tyrosine kinase inhibitor (TKI)
             therapy

          -  =18 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status = 2

          -  Minimum life expectancy of =3 months

          -  Adequate kidney function

          -  Adequate liver function

          -  Normal pancreatic function

          -  Normal QT Fridericia-corrected interval (QTcF) =450 ms for males and =470 ms for
             females

          -  Negative pregnancy test (if woman of childbearing potential)

          -  Agree to use effective form of contraception (as applicable)

          -  Ability to comply with study procedures, in the Investigator's opinion</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Received prior TKI treatment within 7 days prior to receiving the first dose of
             ponatinib, or have not recovered from adverse events (except alopecia) due to agents
             previously administered.

          -  Received other therapies as follows:

               1. For CML chronic phase (CP) and accelerated phase (AP) patients, received
                  hydroxyurea or anagrelide within 24 hours prior to receiving the first dose of
                  ponatinib; interferon, cytarabine, or immunotherapy within 14 days prior to first
                  dose of ponatinib; or any other cytotoxic chemotherapy, radiotherapy, or
                  investigational therapy within 28 days prior to receiving the first dose of
                  ponatinib.

               2. For CML blast phase (BP) patients, received chemotherapy within 14 days prior to
                  the first dose of ponatinib.

               3. For Ph+ ALL patients, received corticosteroids within 24 hours before the first
                  dose of ponatinib; or vincristine within 7 days prior to the first dose of
                  ponatinib; or received other chemotherapy within 14 days prior to the first dose
                  of ponatinib.

          -  Underwent stem cell transplant &lt;60 days prior to receiving first dose of ponatinib

          -  Evidence of on-going graft versus-host disease (GVHD), or GVHD requiring
             immunosuppressive therapy

          -  Taking medications that are known to be associated with Torsades de Pointes

          -  Require concurrent treatment with immunosuppressive agents (other than corticosteroids
             prescribed for a short course of therapy)

          -  Previously treated with ponatinib

          -  CML CP patients are excluded if they are in Complete cytogenetic response (CCyR)

          -  Patients with CML AP, CML BP, or Ph+ ALL are excluded if they are in Major Hematologic
             Response (MaHR).

          -  Have active Central Nervous System (CNS) disease

          -  Have significant or active cardiovascular disease

          -  Have a significant bleeding disorder unrelated to CML or Ph+ALL

          -  Have a history of pancreatitis or alcohol abuse

          -  Have uncontrolled hypertriglyceridemia (triglycerides &gt;450 mg/dL)

          -  Have malabsorption syndrome or other gastrointestinal illness that could affect
             absorption of ponatinib

          -  Diagnosed with another primary malignancy in the past 3 years

          -  Pregnant or lactating

          -  Underwent major surgery within 14 days prior to first dose of ponatinib

          -  Have ongoing or active infection

          -  Suffer from any other condition or illness that would compromise safety or interfere
             with evaluation of the drug</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>449</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/10/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Royal North Shore Hospital, Site #941 - St. Leonards</hospital>
    <hospital>Princess Alexandra Hospital, Site #942 - Woollongabba</hospital>
    <hospital>Royal Adelaide Hospital, Site #951 - Adelaide</hospital>
    <hospital>Peter MacCallum Cancer Center, Site #950 - East Melbourne</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>4102 - Woollongabba</postcode>
    <postcode>5000a - Adelaide</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Cedex 03</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Cedex 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Chesnay Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Monza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Orbassano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam,</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Blk 6 Level 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle-upon-Tyne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ariad Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the efficacy of ponatinib in patients with chronic
      myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or
      with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or
      intolerant to either dasatinib or nilotinib, or have the T315I mutation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01207440</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>